Nuvisan GmbH is a Contract Research Organization (CRO) and Contract Drug Manufacturing Organization (CDMO) providing integrated services across drug development, including DMPK, GMP synthesis, formulation development, bioanalysis and clinical trial supplies. The company was founded on 11 May 2010 and operates six sites in Germany, France and the USA (e.g. Neu-Ulm, Grafing, Waltrop, Sophia-Antipolis and Boston). In fiscal 2024 Nuvisan generated revenue of TEUR 88,257 and employed an average of 467 staff. As of 1 April 2024 the company was fully (100%) acquired by the ALS Ltd. group and is part of its Pharmaceutical & Healthcare division.
Entwicklung, Durchführung, Vermarktung und Vertrieb von pharmakologischen und pharmakokinetischen Untersuchungen und ihrer Ergebnisse.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Memmingen Local Court, HRB 14249 (as of 31 October 2026)
| Name | Type | City |
|---|---|---|
| Achim Freisleben | Geschäftsführer(in) | Grasbrunn |
| Rickard Olofsson | Geschäftsführer(in) | Stara Boleslav |
| Company | Location |
|---|---|
 NUVISAN FRANCE SARL | BIOT |
Source: German Commercial Register (Handelsregister) Memmingen Local Court, HRB 14249 (as of 31 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 28.02.2025 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 04.08.2021 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 18.06.2010 | Company Name Registered | Nuvisan GmbH |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 18.06.2010 | Share Capital Set | — | 25.000 € |
Source: German Commercial Register (Handelsregister) Memmingen Local Court, HRB 14249 (as of 31 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | €18,473,917 | €687,049 | €43,613,141 | 463 |
| 2024 | €88,256,752 | -€1,047,925 | €44,387,292 | 467 |
| 2023 | €77,725,277 | -€2,145,575 | €40,470,323 | 489 |
| 2022 | €81,382,461 | €848,265 | €49,522,376 | 489 |
| 2021 | €83,704,568 | €6,269,270 | €44,806,827 | 432 |
| 2020 | €71,138,805 | €4,264,139 | €38,077,828 | 409 |
| 2019 | €52,328,614 | €2,152,983 | €25,762,516 | 348 |
| 2018 | €32,232,998 | €3,187,555 | €20,579,453 | 335 |
| 2017 | €33,964,357 | €3,063,196 | €16,894,003 | 296 |
| 2016 | €23,568,155 | -€2,350,414 | €16,015,716 | 213 |
Sign in to download data
Source: German Commercial Register (Handelsregister) Memmingen Local Court, HRB 14249 (as of 31 October 2026)
Nipro PharmaPackaging Germany GmbH
Münnerstadt · Herstellung von Flaschen und anderen Behältnissen aus Glas
Aspen Bad Oldesloe GmbH
Bad Oldesloe · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
OmniVision GmbH
Puchheim · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €8,869,414 | 61.0% |
| Material Costs | €4,942,299 | 34.0% |
| Depreciation | €589,627 | 4.1% |
| Interest & Similar | €135,868 | 0.9% |
